A randomized clinical efficacy trial of Hehui capsule against hyperlipidemia

• Published in: Medicine in novel technology and devices Vol. 16; p. 100187
• Main Authors: Ma, Ruiting, Ma, Yuanyuan, Qiao, Junchan, Chen, Lixia, Hou, Mingxing
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.12.2022; Elsevier
• Subjects: Auxiliary lowering blood lipid; Hehui capsule (Hhc); Hyperlipidemia; Auxiliary lowering blood lipid; Hyperlipidemia; Hehui capsule (Hhc)
• ISSN: 2590-0935; 2590-0935
• DOI: 10.1016/j.medntd.2022.100187

Hehui capsule (Hhc) has been used as an assistant treatment for hyperlipidemia. According to the previous studies, miltiorrhiza and Chavica roxburghii may reduce the serum lipid level. This study aims at examining the efficiency of Hehui capsule with regards to treating hyperlipidemia in a randomized control, double-blind clinical trial. In the research, we assigned 104 eligible subjects to Hehui capsule group and placebo groups (52:52, respectively). Subjects used self-control and inter-group controls to compare serum total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL) and other changes before and after the test group and the test group and the control group. During the 45 days intervention, 101 cases were actually included, among which 51 cases for test group, and other 50 cases for placebo group. The total effective rate of blood lipid reduction (90.20%) in the test group was significantly higher than that in the control group (26.00%) (P ​< ​0.01). Together, the result indicates that Hhc has a certain curative effect on dyslipidemia, with no obvious adverse reactions, which can be developed into a new drug for hyperlipidemia. •Hehui capsule against Hyperlipidemia was proved by Double-blind assay.•Other collected data verified that Hhc has non-toxic side effects.•The study provides theoretical support for clinical application of Hehui capsule.